Healing & Recovery
Pentadeca Arginate
PDA · arginate-stabilized BPC successor
What it is
Pentadeca Arginate (PDA) is a newer healing peptide based on the same 15-amino-acid sequence as BPC-157 but bound to an arginate salt for improved stability and bioavailability. It emerged as a popular BPC-157 alternative after FDA scrutiny narrowed compounded BPC-157 availability in 2023–2024.
How it works
Same proposed mechanisms as BPC-157: angiogenesis, collagen synthesis, fibroblast activation, anti-inflammatory effects. The arginate modification may improve absorption and shelf-life. Long-term data is still emerging.
Benefits
- Tendon, ligament, and gut healing
- Soft tissue recovery
- Reduced systemic inflammation
- Improved bioavailability vs. plain BPC-157 (theoretically)
Timeline
- Week 1–2
- Reduced pain and inflammation.
- Week 3–4
- Visible recovery progress.
- Week 6–8
- Major structural healing.
Dosing & titration
Standard dose250–500 mcg subQ daily
Cycle length4–8 weeks
RouteSubQ near injury site if possible
When to titrate upSame as BPC-157 — rarely benefits beyond 500 mcg twice daily.
Side effects & risks
- Limited human data — safety profile assumed similar to BPC-157
- Mild injection site reactions
- Same theoretical angiogenesis/cancer caveat as BPC-157
Newer compound. Long-term human safety data is even thinner than for BPC-157. Most user reports suggest it's well tolerated.
Typical price
$80–$140/mo5 mg vial from a 503A compounding pharmacy.
Studies
- Search PubMed for pentadeca arginate — PubMed searchLive PubMed search
- Reference: BPC-157 literature applies broadly — PubMed search BPC-157Underlying peptide literature
Educational reference only. Not medical advice.